Nursing and Health Professions
Adalimumab
10%
Adverse Event
5%
Biological Product
77%
Biological Therapy
6%
Body Mass
11%
Clinical Outcome
5%
Clinical Practice
5%
Confidence Interval
12%
Decision Tree
10%
Dose
13%
Drug
67%
Drug Therapy
10%
Drug Withdrawal
6%
Etanercept
32%
Evaluation Study
10%
Follow up
10%
Infliximab
20%
Inpatient
65%
Kaplan Meier Method
6%
Log Rank Test
6%
Monotherapy
10%
Multivariate Analysis
6%
Numbers Needed to Treat
20%
Obesity
16%
Patient
97%
Placebo
7%
Procedures
21%
Proportional Hazards Model
6%
Psoriasis
50%
Psoriasis Area and Severity Index
35%
Psoriasis Vulgaris
18%
Secukinumab
100%
Socialized Medicine
10%
Standard
10%
Survival
43%
Time
10%
Ustekinumab
72%
Medicine and Dentistry
Adalimumab
8%
Adult
10%
Adverse Event
5%
Arthritis
25%
Biological Product
37%
Biological Therapy
6%
Case Report
33%
Chemotherapeutic Agent
54%
Combination Therapy
25%
Crohn's Disease
8%
Cyclosporine
8%
Dermatology
6%
Development
8%
Drug
54%
Drug Withdrawal
6%
Etanercept
14%
Etretin
8%
Exanthem
8%
Follow up
8%
Incidence
8%
Inpatient
8%
Kaplan Meier Method
6%
Life
12%
Log Rank Test
6%
Multivariate Analysis
6%
Nail
8%
Obesity
16%
Patient
38%
Photochemotherapy
8%
Proportional Hazards Model
6%
Psoriasis
64%
Psoriasis Area and Severity Index
20%
Psoriasis Vulgaris
22%
Psoriatic Arthritis
16%
Pustulosis Palmaris Et Plantaris
25%
Recurrent Disease
8%
Sarcoidosis
8%
Scalp
8%
Skin Defect
8%
Survival
43%
Therapeutic Agent
8%
Therapeutic Procedure
81%
Therapy Effect
8%
TNF Inhibitor
16%
Topical Corticosteroid
16%
Tumor Necrosis Factor
8%
Ustekinumab
69%
Woman
8%
Pharmacology, Toxicology and Pharmaceutical Science
Adalimumab
8%
Adverse Event
5%
Antagonist
16%
Biological Product
37%
Ciclosporin
8%
Crohn Disease
8%
Drug
54%
Etanercept
14%
Etretin
8%
Incidence
8%
Inflammatory Bowel Disease
8%
Obesity
16%
Observational Study
12%
Paradoxical Reaction
8%
Psoriasis
64%
Psoriasis Vulgaris
22%
Psoriatic Arthritis
16%
Pustulosis palmoplantaris
25%
Rash
8%
Recurrent Disease
8%
Retrospective Study
12%
Rheumatoid Arthritis
25%
Sarcoidosis
8%
Skin Defect
8%
Survival
43%
Tumor Necrosis Factor
8%
Tumor Necrosis Factor Inhibitor
16%
Ustekinumab
69%
